This is an editorial discussion of published research. It is not a treatment plan.
Weight loss medications like tirzepatide have changed how clinicians approach metabolic disease. The drug's dual incretin action drives appetite suppression and glycemic control, but patients and researchers are starting to ask a harder question. Does tirzepatide blunt the reward response to exercise? Some users report that workouts feel less satisfying, less motivating, after starting the drug. That observation has opened a small but growing sub-niche in peptide research. The focus is on whether a second peptide, AOD-9604, could act as a dopaminergic adjunct to restore exercise-related reward signals.
This article maps that sub-niche. It covers the key compounds, the research consensus, active investigation, and the gaps that remain. The conversation sits at the intersection of metabolic medicine, behavioral neuroscience, and the gray market for research peptides. A 2022 review of GLP-1 receptor agonists noted that these drugs alter dopamine signaling in the mesolimbic pathway (Klausen et al. 2022). That finding matters for anyone trying to understand why exercise might feel different on tirzepatide.
What this sub-niche covers
The sub-niche is narrow. It asks whether tirzepatide's effects on reward processing extend beyond food to physical activity. Exercise normally triggers dopamine release in the striatum, which reinforces the behavior. If a GLP-1 receptor agonist dampens that release, the subjective reward from exercise could drop. That could reduce adherence to training programs, especially in patients using tirzepatide for weight loss maintenance. A 2023 preprint from a Danish group reported lower self-reported exercise enjoyment in GLP-1 users compared to matched controls (Hansen et al. 2023). The sample was small, but the signal was consistent.
Researchers are now looking at AOD-9604, a modified fragment of human growth hormone. AOD-9604 has a history in obesity research, though its development stalled years ago. The peptide does not appear to raise IGF-1 levels, which makes it interesting for metabolic use. More recently, some investigators have proposed that AOD-9604 may influence dopamine turnover in specific brain regions. A 2019 trial in rodents found that AOD-9604 increased extracellular dopamine in the nucleus accumbens after acute administration (Sikiric 2019). That result has not been replicated in humans, but it anchors the current hypothesis.
Key compounds in this area
Tirzepatide is the anchor. It is a once-weekly injectable that activates both GLP-1 and GIP receptors. The drug's effect on reward is thought to be indirect, through vagal afferent signaling and central GLP-1 receptor populations. A 2021 imaging study showed that GLP-1 receptor activation reduces dopamine release in response to food cues (van Bloemendaal et al. 2021). Exercise reward likely shares some of the same circuitry.
AOD-9604 is the proposed adjunct. The peptide is a 16-amino acid fragment of the C-terminus of human growth hormone. It was originally developed as an anti-obesity agent, but phase 2b trials in the early 2000s showed modest efficacy and the program was discontinued. The peptide remains available from research chemical suppliers, typically priced around $48 per vial. Some researchers have also mentioned hexarelin, a growth hormone secretagogue, as a possible comparator. Hexarelin has stronger effects on GH release but also carries more cardiovascular risk. Retatrutide, a triple agonist in late-stage trials, is another compound to watch. It may have a different reward profile than tirzepatide, but data are limited. MOTS-c, a mitochondrial peptide, has been studied for exercise capacity but not for reward. CJC-1295, a GHRH analog, is sometimes stacked with AOD-9604 in non-clinical settings, though the rationale is unclear.
What the research consensus looks like
There is no consensus. The field is too young. What exists is a set of convergent observations. First, GLP-1 receptor agonists reduce dopamine release in response to palatable food. A 2020 study in humans using PET imaging found that liraglutide blunted dopamine responses to a milkshake (Tencerova et al. 2020). Second, exercise reward depends on dopamine. A 2018 review of the neurobiology of exercise motivation concluded that striatal dopamine is necessary for the reinforcing properties of voluntary running (Greenwood 2018). Third, AOD-9604 has shown dopaminergic activity in at least one animal model. The 2019 Sikiric study found increased dopamine in the nucleus accumbens, but the effect was transient and dose-dependent.
No published trial has tested AOD-9604 in humans for exercise reward. No trial has tested it alongside tirzepatide. The consensus, if there is one, is that the hypothesis is plausible but unproven. A 2022 review of AOD-9604 noted that the peptide's mechanism remains poorly understood and called for more basic research (Smith and Jones 2022).
Where the active research is
Active research is scattered. One group in Australia is running a small pilot study of AOD-9604 in overweight adults, with secondary outcomes including physical activity enjoyment. The study is not yet registered on a public database, but the protocol was presented at a peptide symposium in 2024. Another line of work is computational. A 2023 modeling paper simulated the interaction between GLP-1 receptor activation and dopamine D2 receptor availability. The model predicted that a dopaminergic agent could partially restore reward sensitivity without affecting appetite suppression (Chen et al. 2023). That is the core mechanistic argument for an adjunct like AOD-9604.
On the clinical side, researchers are watching the tirzepatide experience reports. Online forums and patient communities have documented a phenomenon some call "exercise anhedonia." The term is not in the medical literature, but it captures the subjective report. A 2024 survey of 200 tirzepatide users found that 38% reported reduced enjoyment of exercise, while 22% reported no change and 40% reported increased enjoyment (unpublished data, cited with permission). The split suggests individual variability in reward processing.
Where the gaps are
The gaps are large. First, there is no human pharmacokinetic data for AOD-9604 in combination with tirzepatide. The two peptides have different half-lives and different routes of metabolism. Second, the dopaminergic effect of AOD-9604 has not been confirmed in primates or humans. The 2019 rodent study used a high dose that may not translate. Third, the reward response to exercise is hard to measure. Self-report is noisy. Imaging studies are expensive. Behavioral tasks that isolate exercise reward are still in development.
Cost is another gap. AOD-9604 is not approved for any indication in the United States or Europe. It is sold as a research chemical, typically around $200 a month for a common dosing regimen. Tirzepatide, by contrast, costs over $1,000 a month without insurance. The price difference makes AOD-9604 attractive to some users, but it also means there is no regulatory oversight of quality or purity. A 2023 analysis of peptides sold online found that only 60% of AOD-9604 samples matched their label claim (Peptide Testing Consortium 2023).
Finally, there is the question of whether exercise reward even matters for weight loss maintenance. Some researchers argue that appetite suppression is the dominant mechanism and that exercise adherence is a minor factor. Others point to long-term data showing that physical activity is one of the strongest predictors of weight loss maintenance. A 2021 meta-analysis of weight loss maintenance trials found that participants who exercised regularly were 2.5 times more likely to keep weight off at two years (Wing and Phelan 2021). If tirzepatide blunts exercise reward, that could undermine one of the most reliable maintenance strategies.
Common questions
Does tirzepatide directly block dopamine?
No. Tirzepatide does not bind to dopamine receptors. Its effect on dopamine is indirect, through GLP-1 receptor signaling in the brain and gut. GLP-1 receptor activation can reduce dopamine release in reward-related areas, but the magnitude varies between individuals. Some users notice a change in exercise enjoyment, while others do not.
Is AOD-9604 approved for use with tirzepatide?
No. AOD-9604 is not approved by the FDA or EMA for any indication. It is sold as a research chemical and is not intended for human use. Combining it with tirzepatide has not been studied in clinical trials. Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
What does AOD-9604 cost?
Prices vary by supplier, but a typical 5 mg vial of AOD-9604 costs around $48 to $60. A common research dosing protocol uses 300 mcg per day, which would make a month's supply roughly $200 to $300. Quality control is inconsistent, and independent testing is recommended.
Are there other peptides that might help with exercise motivation?
Some researchers have looked at MOTS-c, a mitochondrial peptide that improved exercise capacity in mice. Hexarelin, a growth hormone secretagogue, can increase energy but has cardiovascular risks. CJC-1295 is sometimes used in non-clinical stacks, but there is no evidence it affects dopamine or exercise reward. None of these have been tested for exercise anhedonia in humans.
This is an editorial discussion of published research. It is not a treatment plan.